University of Texas MD Anderson Cancer Center
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From University of Texas MD Anderson Cancer Center
NIH’s National Cancer Institute licensed two experimental cancer therapies in the past month to biopharma firms, leading a heavy slate of cancer-focused tech transfer deal-making.
Private Company Edition: TVM, Focus/MD Anderson and RA Capital launched new venture capital funds. Also, LianBio’s $310m crossover financing, AavantiBio’s Sarepta-backed $107m series A and Sirnaomics’ $105m series D led recent VC rounds.
Cancer deals involve City of Hope/Chimeric, CARISMA/NYU, Sorrento/Mayo Clinic, Rain/Drexel, Diaprost/Memorial Sloan Kettering, Alkido/University of Kentucky. Plus, research collaborations in brief.
New York biotech is partnering with researchers at Columbia, Kansas State and Southern Research to address the pandemic.
- Academic and Research Institutions